Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Inclusion Criteria: * A diagnosis of small lymphocytic lymphoma, follicular lymphoma (grades 1-3a), or marginal zone lymphoma * Evidence of progression or lack of response following at least 1 prior treatment for indolent lymphoma * Able and willing to provide written informed consent and to comply with the study protocol * Must have at least 1 node greater than 1.5 cm in short axis diameter * Adequate hematologic function (unless abnormalities are related to NHL), defined as follows: * Hemoglobin \>= 9.0 g/dL * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L; ANC \< 1.5 x 10\^9/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physician * Platelet count (PLT) \>= 75 x 10\^9/L; PLT count less than 100 x 10\^9/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physician * For men who are not surgically sterile, agreement to use a barrier method of contraception for \>= 3 months after the last obinutuzumab dose; in addition, male patients must agree to request that their partners use an additional method of contraception, such as oral contraceptives, intrauterine device, barrier method of contraception, or spermicidal jelly * For women of reproductive potential who are not surgically sterile, agreement to use two adequate methods of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly for \>= 1…